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Background: The aim of this study was to investigate the effects of chronic treatment with carvedilol in blood
pressure (BPV) and heart rate (HRV) variability of rats with myocardial infarction (MI).
Methods:MI was produced in male rats by ligature of anterior interventricular branch of left coronary artery.
Control rats were submitted to a sham surgery (SO). MI and SO rats were randomized to receive for 30 days
placebo (Plac 0.5% metilcelulose) or carvedilol (Carv, 2 mg/Kg body weight/day, drinking water): SO-Plac
(N = 10), SO-Carv (N = 10), MI-Plac (N = 12), MI-Carv (N = 13). Blood pressure (BP) was directly
recorded in the awake animals and BPV was determined, in time (variance, mmhg2) and frequency domains
by the autoregressive method. Statistical signiﬁcance was set in P b 0.05. Data are median and interquartile
range.
Results: No signiﬁcant changes in HRV was observed in MI rats, while BPV showed signiﬁcant decreasing of
blood pressure variance (SO-Plac = 42.08 (39.21) mmHg2 vs. MI-Plac = 21.67 (12.58) mmHg2, P b 0.05),
reversed by the Carv treatment (MI-Plac = 21.67 (12.58) vs. MI-Carv = 38.64 (29.25), P b 0.05). In the fre-
quency domain analyses, MI reduced absolute and normalized LF component (LF (mmHg2): SO-Plac = 8.98
(14.84) vs. MI-Plac = 2.08 (4.84), P b 0.05; LF(nu): SO-Plac = 79.48 (45.03) nu vs. MI-Plac = 24.25 (40.67)
nu, P b 0.05) and increased the normalized HF component of the BPV (SO-Plac = 20.51 (39.18) vs.
MI-Plac = 60.51 (39.73). Carv treatment signiﬁcantly attenuated the LF component fall.
Conclusion: Chronic treatment with carvedilol restored the variance of BPV altered by the MI.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cardiovascular diseases represent today the major cause of death
and disability in the world (World Health Organization, 2008;
Gaziano et al., 2010; Mittal and Singh, 2010). Ischemic heart diseases
have accounted for about 7.2 millions of deaths in 2004 (World
Health Organization, 2008). Blood pressure (BP) is one of the most
important parameters to maintain cardiovascular homeostasis and
its regulation depends on a complex beat-to-beat and long-term inte-
gration of efferent signals in the central nervous system to produce
ﬁne adjustments of the autonomic balance to the heart and blood ves-
sels, thus modulating heart rate, cardiac output and peripheral vascu-
lar resistance. In pathological conditions, either afferent as well asyocardial infarct; HRV, heart
ency; HF, high frequency; SO,
8, Maruípe, Vitória-ES,
7330.
s).
rights reserved.efferent signaling may change, and thus affect BP regulation. For the
better understand the hemodynamic deregulation occurring in sever-
al cardiovascular diseases, studies of patterns of blood pressure vari-
ability (BPV) have received increasing attention because it may
provide sign of risk of cardiovascular death (Akselrod et al., 1985;
Mancia et al., 1994; Martinka et al., 2005) and valuable information
on the mechanisms of cardiovascular deregulation (Pagani et al.,
1988).
The impact of myocardial infarction (MI) on BPV has received little
attention until now, mainly in experimental animals in which, unlike
the studies in humans, a more detailed exploration of variables inter-
fering in blood pressure regulation is possible (Mostarda et al., 2010).
Long-term use of beta-blockers has been strongly recommended to
prevent cardiac arrhythmias and cardiac death in patients with MI
(Gunnar et al., 1990). Since adrenergic blockers interfere on the effer-
ent sympathetic control of heart rate and vascular resistance, studies
on BPV under such drugs inﬂuence are clinically relevant. Carvedilol
is a non-selective beta-blocker also exhibiting alpha-1 blockade prop-
erties with increasing use in patients with MI and heart failure
(Packer et al., 1996a, 1996b; Dargie, 2001). However, the long-term
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Therefore, we carried out this study to investigate the interference
of chronic use of carvedilol on the spectral and temporal parameters
of BPV of rats submitted to MI.
2. Materials and methods
2.1. Sample and myocardial infarct procedure
Fifty-one male Wistar rats of our department colony were used in
the experiments. The study was approved by our institutional ethical
committee (Ethics Committee in Use of Animals, protocol no. 056/11)
and the experiments were conducted in accordance with the Guide
for Care and Use of Laboratory Animals published by the US National
Institute of Health (NIH Publication #85-23, revised 1996). The
animals (8 to 10 weeks old) were anesthetized (35 mg/kg
Ketamine + 10 mg/kg Xylazine, im), the thorax was opened in the
fourth left intercostal space, the heart was rapidly eviscerated and a
6–0 mononylon thread was used to produce a permanent ligature of
the anterior interventricular branch of left coronary artery (N = 31),
as before described (Mill et al., 1992). Another group of rats was
subjected to a sham operation (SO, N = 20), in which the coronary
ligature around the coronary vessels was not tied. Twenty-four hours
later, the rats were re-anesthetized with the same drugs to record a
standard electrocardiogram (ECG). Presence of MI was conﬁrmed by
the presence of wide Q wave in D1 lead (Pimentel et al., 2012). Six
rats were excluded from the study because Q wave was absent,
suggesting an unsuccessful coronary ligature. The MI (N = 25) and
SO groups were then randomized to receive a daily treatment with car-
vedilol (Carv, 2 mg/Kg) or placebo (Plac, 0.5% methylcellulose vehicle)
in the drinking water. The volume of water supplied was determined
by the average weekly consumption in a pilot study. The rats were
kept in a room with controlled temperature (20–22 °C) with 12:12-h
light–dark-cycle and food was provided ad libitum.
2.2. Hemodynamic evaluation of blood pressure and ECG acquisition
The treatment was discontinued onemonth later. The rats were then
weighted, anesthetized (90 mg/Kg Ketamine + 13 mg/Kg Xylazine, ip)
to insert a PE50 catheter into the left femoral artery to direct BP record-
ing and to implant metallic electrodes under the skin to ECG recording.
After 24 h, the arterial cannulawaswashedwith saline heparinized solu-
tion (1:500 UI) and attached to a pressure transducer (TRA021, LSI,
Letica, Scientiﬁc Instruments) to blood pressure monitoring (sampling
rate 2 KHz). Simultaneously the metallic electrodes were connected to
the input of a bioelectric ampliﬁer (ML 132 Bio Amp) to record ECG
(sampling rate 2 KHz). The pulsatile blood pressure and the ECG
signals were simultaneously processed in a data acquisition system
(Powerlab 4 sp, sp 4922, Adinstruments; Bridge Amp, ML 110) and
analyzed in a dedicated computer with Chart 5.5.1 software. After
adaption to the recording system, blood pressure and ECG were con-
tinuously recorded for 30 min. Systolic, diastolic and mean blood
pressure as well as heart rate were averaged during the 30 min re-
cording period to give basal values of these variables in the awake
and unrestrained animals.
2.3. Blood pressure and heart rate variability
Time and frequency domains analyses of systolic BPV and HRV
were obtained from the 30 min recording period. An algorithm was
used to detect cycle-to-cycle peak systolic pressure and R waves,
thus generating the beat-to-beat series of systolic pressure and R–R
intervals. The series were visually inspected and artifacts and ectopic
beats were manually removed (Task Force, 1996). Time domain anal-
ysis included variance of systolic BP and variance of R–R intervals in
the entire record. Frequency domain analysis was performed byautoregressive modeling with model order set in 16 (Dantas et al.,
2012). Oscillatory components were calculated by the Yule–Walker
method with the Levison Durbin recursion (Souza et al., 2008). The
oscillatory components were divided in following bands: very low
frequency (VLF, 0.01–0.20 Hz), low frequency (LF, 0.20–0.75 Hz) and
high frequency (HF, 0.75–2.50 Hz) (Malliani et al., 1991). Low and
high frequency components were expressed also in normalized units.
Normalization consisted in dividing the power of a given spectral
component by the total power minus the power of VLF andmultiplying
the ratio by 100. LF/HF ratio was obtained by division of the compo-
nents of low by high frequency, in normalized units (Malliani et al.,
1991).
2.4. Evaluation of cardiac weight and structure
After hemodynamic recording, the ratswere anesthetized (90 mg/Kg
Ketamine + 13 mg/Kg Xylazine, ip) and euthanatized with an
intravenous injection of 3 M KCl. The thorax was opened, the heart
quickly removed, washed in saline solution, dried on paper-ﬁlter,
weighed (atria and ventricles), wrapped in plastic, and stored for
30 min at −12 °C. The atria were then removed and the ventricles
were cut transversely into four equal segments, from the apex to
the base. The sections were immersed in a 10% tripheniltetrazolium
chloride solution at 37 °C for 10 min, and ﬁnally immersed in 10%
buffered formalin solution for 20 min. This procedure allowed
increasing the contrast between the intact myocardial and the in-
farct scar. Images of sections were scanned (Scanjet 2400) and an-
alyzed by planimetry with a software (Image J 1.40 g). Infarct size,
expressed as percentage, was calculated by dividing the sum of in-
farct areas from all sections by the sum of left ventricle areas from
all sections (including those without infarct scar) and multiplying
by 100 (Takagawa et al., 2007). Relative heart weight was calculat-
ed dividing heart weight by body weight.
2.5. Statistical analyses
Normality of data was evaluated by Shapiro–Wilk test and vari-
ance homogeneity by Levene test. MI size was compared with two-
tail unpaired t-test. Body weight, relative cardiac weight, heart rate,
BPV and HRV variables, were ranked before comparisons. These vari-
ables, and the hemodynamic parameters (systolic, diastolic, and
mean blood pressures), body weight and cardiac weight were com-
pared by two-way ANOVA followed by the Bonferroni post hoc test
for multiple comparisons. Only the following comparisons between
groups were tested in the post-hoc test: SO-Plac vs. SO-Carv (to test
the effect of the Carv), SO-Plac vs. MI-Plac (to test the effect of the
infarct) and MI-Plac vs. MI-Carv (to test the effect of Carv in presence
of MI). Statistical signiﬁcance was set in P b 0.05 and SPSS 15.0 was
used to perform all analyses. Unless otherwise stated, data are
expressed as mean ± standard deviation.
3. Results
Body weight before surgery was similar in the four groups
(SO-Plac = 245 ± 12 g; SO-Carv = 250 ± 7 g; MI-Plac = 238 ±
9 g; MI-Carv = 223 ± 5 g; P > 0.05; two-way ANOVA). The body
weight gain during the treatment period was similar in the four
groups, so that the ﬁnal body weight was also similar in the four
groups at the end of the study (SO-Plac = 376 ± 19 g; SO-Carv =
384 ± 7 g; MI-Plac = 362 ± 11 g; MI-Carv = 328 ± 7 g; P > 0.05;
two-way ANOVA).
3.1. Cardiac structure
No visible scar was observed in rats submitted to sham surgery,
while a remarkable transmural scar was observed in all animals
Table 1
Hemodynamic data measured during 30 min in awake and unrestrained rats.
SO-Plac
(N = 10)
SO-Carv
(N = 10)
MI-Plac
(N = 13)
MI-Carv
(N = 12)
SBP (mmHg) 125 (8) 126 (10) 118 (12) 117 (15)
MBP (mmHg) 103 (7) 101 (8) 99 (12) 94 (10)
DBP (mmHg) 92 (5) 89 (7) 89 (12) 83 (9)
HR (bpm) 353 (54) 331 (70) 367 (83) 349 (51)
Values are median and interquartile range (p75–25). SO-Plac – Sham operated place-
bo; SO-Carv – Sham Operated Carvedilol; MI-Plac – myocardial infarction placebo;
MI-Carv – myocardial infarction carvedilol; SBP – systolic blood pressure; MBP –
mean blood pressure; DBP – diastolic blood pressure; HR – heart rate. No signiﬁcant
differences were found. All data were compared by two-way ANOVA. HR was ranked
before comparisons.
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vedilol treatment (MI-Plac = 33 ± 7 % vs. MI-Carv = 37 ± 12%;
P > 0.05). Fig. 1 shows the absolute and relative weight of the heart
in the four groups. A signiﬁcant increase of the cardiac weight was
observed in the untreated infarcted group, which was fully prevented
by carvedilol treatment.
3.2. Hemodynamic data
The hemodynamic data recorded in the awake and unrestrained
rats one month after coronary ligature or sham surgery are shown
in Table 1. Data have shown that the infarcted rats were hemodynam-
ically stabilized since BP and heart rate values were like non-infarcted
animals. No signiﬁcant differences was found between groups, al-
though a slight tendency to reduced BP and heart rate values were
observed in infarcted group treated with carvedilol.
3.3. BPV analyses
A notable decrease in several components of time and frequency
domains of BPV was observed in rats with healed infarction
(Table 2). The only parameter without signiﬁcant reduction was the
HF component (absolute units), which is more dependent on oscilla-
tion of venous return due to respiratory movements. Nevertheless,
when this same spectral component was evaluated in normalized
units, signiﬁcant differences were observed in infarcted rats. Carvedil-
ol given to sham-operated animals did not produce signiﬁcant
changes in none of the parameters analyzed. However, carvedilol
treatment prevented changes in BPV after infarction. Spectral indexes
of BPV also tended to increase after chronic carvedilol treatment, but
without statistical signiﬁcance. Noteworthy, there was a signiﬁcantFig. 1. Cardiac weight. a – Absolute weight. b – Relative weight. a– Values are mean ±
standard deviation. b – Box plot. SO-Plac – Sham operated placebo; SO-Carv – Sham
operated carvedilol; MI-Plac –myocardial infarction placebo; MI-Carv –myocardial in-
farction carvedilol. P b 0.05: #SO-Plac vs. MI-Plac; *MI-Plac vs. MI-Carv. Cardiac
weights were compared by two-way ANOVA followed by Bonferroni post hoc test. Rel-
ative cardiac weight was ranked before comparisons.change in the proportion of LF and HF normalized values after infarc-
tion, with a remarkable decrease of LF component and an increase of
HF component in infarcted as comparison with non-infarcted rats.
3.4. HRV analyses
Absolute indexes of HRV were not signiﬁcantly altered by MI
(Table 3). Nevertheless, a tendency to reduction in parasympathetic
modulation (observed by a non-signiﬁcant decrease of normalized
HF) was seen in infarcted animals. Conversely, treatment with carve-
dilol tended to increase all HRV variables and to restore the values of
the normalized HF component.
4. Discussion
Our study assessed the effect of chronic treatment with carvedilol
on BPV in rats underwent MI. Previous studies (Detollenaere et al.,
1993; Kardos et al., 1996; Mostarda et al., 2010) evaluated BPV in
MI, but to our knowledge, this was the ﬁrst study that investigated
the effect of long-term treatment with carvedilol on BPV in an exper-
imental infarction model.
It is known that HF component of HRV is a marker of vagal modu-
lation of heart beats (Task Force, 1996), while the HF power of BPV
reﬂects oscillations of pressure caused by respiratory movements, in-
volving also ﬂuctuations of the cardiac output of purely mechanical
origin (Julien et al., 1995). Some authors have argued that the LF
band can be considered as a marker of sympathetic activity driven
to sinoatrial node and peripheral vasculature (Pagani et al., 1988;
Parati et al., 1995). Others have shown that this HRV component is
inﬂuenced by both sympathetic and parasympathetic components
of the autonomic nervous system (Pomeranz et al., 1985), according
to data obtained with pharmacological manipulation of the autonom-
ic nervous system. In the present study, 30 days after MI or shamTable 2
Blood pressure variability analyses.
SO-Plac
(N = 10)
SO-Carv
(N = 10)
MI-Plac
(N = 13)
MI-Carv
(N = 12)
Variance of SBP
(mmHg2)
42.08 (39.21) 48.17 (30.34) 21.67 (12.58)# 38.64 (29.25) *
VLF (mmHg2) 12.05 (13.09) 21.25 (10.58) 8.84 (3.51) 11.94 (6.73)
LF (mmHg2) 8.98 (14.84) 11.55 (11.11) 2.08 (4.84)# 3.80 (4.10)
HF (mmHg2) 2.97 (2.73) 4.63 (3.27) 4.17 (3.42) 5.88 (4.24)
LF (n.u.) 79.48 (45.03) 69.10 (15.35) 24.25 (40.67)# 31.53 (33.08)
HF (n.u.) 20.51 (39.18) 30.54 (14.67) 60.51 (39.73)# 68.46 (34.36)
Values are median and interquartile range (p75–25). SO-Plac – Sham operated place-
bo; SO-Carv – Sham operated carvedilol; MI-Plac – myocardial infarction placebo;
MI-Carv – myocardial infarction carvedilol; SBP – systolic blood pressure; VLF – very
low frequency; LF – low frequency; HF – high frequency; n.u. – normalized units.
P b 0.05: #SO-Plac vs. MI-Plac; *MI-Plac vs. MI-Carv. All variables of blood pressure var-
iability were ranked and compared by two-way ANOVA. Multiple comparisons were
performed by Bonferroni test, when signiﬁcant differences were found.
Table 3
Heart rate variability analysis.
SO-Plac
(N = 10)
SO-Carv
(N = 10)
MI-Plac
(N = 13)
MI-Carv
(N = 12)
Variance of
R–R (ms2)
63.83 (49.54) 107.25 (135.92) 65.83 (148.93) 154.80 (183.80)
VLF (ms2) 14.71 (9.51) 30.30 (44.17) 21.06 (42.79) 54.95 (45.89)
LF (ms2) 3.11 (2.51) 7.61 (9.76) 4.15 (5.78) 8.82 (19.84)
HF (ms2) 13.31 (9.79) 22.08 (35.16) 18.41 (30.81) 47.75 (38.27)
LF (nu) 14.91 (6.29) 18.49 (22.44) 15.61 (14.40) 16.99 (17.48)
HF (nu) 68.08 (22.00) 68.90 (13.74) 54.94 (22.85) 66.62 (11.80)
LF/HF ratio 0.21 (0.90) 0.29 (0.37) 0.26 (0.22) 0.26 (0.33)
Values are median and interquartile range (p75–25). SO-Plac – Sham operated place-
bo; SO-Carv – Sham Operated Carvedilol; MI-Plac – myocardial infarction placebo;
MI-Carv – myocardial infarction carvedilol; VLF – very low frequency; LF – low fre-
quency; HF – high frequency; n.u. – normalized units. No signiﬁcant differences were
found. All data were ranked and compared by two-way ANOVA.
234 E.M. Dantas et al. / Autonomic Neuroscience: Basic and Clinical 177 (2013) 231–236surgery the HRV analysis has shown similar values between infarcted
and non-infarcted rats and treatment with carvedilol seems has not
affected the results. Acute carvedilol administration to awake rats
produces intense bradicardia and depression of LF component of
HRV (Bertera et al., 2012). However, a fast liver metabolization occurs
so that normal heart rate values are recovered after 90 min. In our
study, carvedilol treatment was interrupted 24 h before blood pres-
sure recording. Therefore, it is likely that our data are related to
chronic adaptations to carvedilol treatment and do not represent
acute effects of the drug. However, according to previous studies, an
increase sympathetic drive directed to the heart and blood pressure
would be expected in untreated infarcted rats. Changes in sympathet-
ic drive, however are depends on time course of heart failure devel-
opment. A transient tachycardia is observed in the acute infarct
phase that resumes during infarct healing (Francis et al., 2001). In
our study, animals were investigated in a compensated phase of in-
farction exhibiting normal values of heart rate in basal conditions.
Therefore, even in presence of infarction, a normal autonomic balance
directed to heart seems to be present in the studied animals. It is pos-
sible that larger infarcts than those used in the present study would
produce different results in relate to basal hemodynamic values and
HRV.
Few experimental studies have investigated changes of BPV after
MI. One of them (Mostarda et al., 2010) evaluated the spectral index-
es of BPV three months after coronary ligature, and an important in-
crease of the LF component (measured in absolute units) was
observed, without any change in the HF component. Our study
showed an overall decrease of BPV in the rats with healed MI, a ﬁnd-
ing partially prevented in the infarcted group submitted to the chron-
ic use of carvedilol. Our data agreed with a previous study (Kardos et
al., 1996) that also found decreased BPV in patients 3–5 days after in-
farction. BPV is linked to beat-to-beat changes in stroke volume. Thus,
these authors hypothesized that the BPV attenuation could be related
to a relative invariance of stroke volume caused by a reduced left ven-
tricular compliance. In our results, we observed decreased values of
the systolic pressure variance and LF component (absolute and nor-
malized) and an increase of the normalized HF. However, BPV
changes seen in the present study are in accordance with pathophys-
iological alterations reported in literature (Van de Borne et al., 1997;
Notarius et al., 1999; Ohte et al., 2012). The LF component coincides
with the slow blood pressure waves (Mayer’s waves) is a marker to
the vascular sympathetic activity modulated by baroceptor reﬂex,
and its increase is expected in diseases that coursing with increases
of the sympathetic efference. However, the LF rise does not occur
always, and its increment or decrement seems be depend of the am-
plitude of sympathetic modulation, which is closely related to time
course and severity of a disease, such as occurs in acute stages of MI
until chronic stages of the heart failure. Thus, previous studies(Guzzetti et al., 1995; Van de Borne et al., 1997; Notarius et al.,
1999; Ohte et al., 2012) have shown that in moderated-to-severe
heart failure, chronic high catecholamine levels produced by chronic
sympathetic discharge may produce uncoupling of adrenergic recep-
tors (possibly by down-regulation) thus decreasing the power of LF
oscillatory component, or still that the loss of central rhythmical
modulation of sympathetic discharge to the periphery. This explains
the strange paradox of sympathetic excess activity and the fall of LF
BPV (and HRV) component in presence of chronic heart failure. More-
over, it was reported in clinical and experimental studies (Kruger
et al., 1997; La Rovere et al., 1998) that sympathetic vasomotor baro-
reﬂex sensitivity decreases after MI. Interestingly, conversely of
reported on experimental studies in sino-aortic denervation (Di
Rienzo et al., 1991; Rodrigues et al., 2011), the variance of blood pres-
sure had shown a notable decreasing after myocardial infarction.
Although a great increase in blood pressure variance was expected
due to withdrawal of baroceptor activity, which could be a mecha-
nism to attenuate high blood pressure changes, the data of our
study appear to counter this hypothesis. Rats submitted to MI had a
marked reduction on BPV. These results are in accordance with
short or long-term observations in subjects with heart failure, in
which BPV is also decreased (Caruana et al., 1988; Guzzetti et al.,
1995; Giles et al., 2001). Our results also had shown a signiﬁcant
increase of normalized HF BPV component. It was reported that
hypoxemia in presence of heart failure or the reduced perfusion of
aortic and carotid bodies may produce hyperexcitation of chemical-
receptors and sympathetic activation even in presence of decreased
baroreﬂex sensitivity (Kara et al., 2003). Once this component is high-
ly affected by respiration, it is likely that increase of peripheral
chemical-receptors discharges may account for the increment of HF
values.
In clinical context, the effect of carvedilol treatment was previous-
ly evaluated (Piccirillo et al., 2000) on HRV and BPV in subjects with
heart failure. However, the identiﬁcation of carvedilol effects in clini-
cal setting is difﬁcult to evaluate, since beta-blockers are usually used
in combination with other drugs in patients with heart failure. In this
work (Piccirillo et al., 2000), for example, patients were also under
the effects of other drugs, such as digoxin, enalapril, and furosemid.
The digoxin shows direct effect on vascular smooth muscle, while
enalapril blocks the synthesis of angiotensin-II. Therefore, both treat-
ments are able to interfere in the BPV, mainly in the LF component,
and thus, in the peripheral vascular tone. The carvedilol treatment
improve the HRV, increasing the total power of spectrum and abso-
lute (LF and HF) and HF normalized components, decreasing the LF
normalized and the LF/HF ratio, suggesting a reduction in the sympa-
thetic modulation simultaneously to an increased vagal modulation
directed to the heart. With regard to BPV, it was observed a decreas-
ing in the LF normalized, that the authors attributed to effect of
reduction in sympathetic modulation to the vessels due adrenergic-
blocker effect of carvedilol on α-1 receptors, and an increasing of
normalized HF. These data, nevertheless, are of restricted comparabil-
ity to the studies with experimental animals. In the present study, the
carvedilol treatment was started in acute stage of MI, before chronic
heart failure development. Moreover, the carvedilol was tested as
only drug in animals with and without MI. Other studies (Mortara
et al., 2000; Bullinga et al., 2005) also reported beneﬁt of carvedilol
treatment on HRV, showing increasing of vagal modulation, decreas-
ing in sympathetic modulation and increasing the total power of
spectrum.
The increasing of cardiac weight constitutes an important marker
of cardiac remodeling in infarcted heart, and this fact occurred in
infarcted rats without treatment. Carvedilol treatment prevented
the weight increasing. This result agreed with a previous study
(Watanabe et al., 2000) that has shown increasing of cardiac weight
in rats with heart failure, and normal cardiac weight when the rats
were treated with carvedilol.
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and heart failure are evolving process. Therefore, longitudinal obser-
vations of hemodynamic parameters should provide better informa-
tion about the efﬁcacy of pharmacological treatments to maintain
physiological variables under normal values despite the harm to
mechanical performance of infarcted hearts. However, assessment
of BPV needs precise measurement of systolic blood pressure. Thus,
invasive BP recording techniques are mandatory in such conditions.
Our data, therefore, were related only to rats surviving to infarction
and nearly 50% of the rats died after coronary ligature. Mortality,
however, was similar in rats treated or untreated with carvedilol.
Therefore, we cannot rule out the possibility that effects produced
by beta-blockade occurred only in the sub-group of animals with bet-
ter survival after coronary ligature. Moreover, our evaluations were
focused in methods of power spectral analyses, and thus, more two
issues should be communicated. First, we did not use a speciﬁc test
to assess the stationarity of the analyzed series. The stationarity hy-
pothesis was assumed because short length frames were used in the
analyses. However, it has been shown (Magagnin et al., 2011) that
non-stationarities are frequently present even in well-controlled
experiments, which potentially might biasing the spectral indices. In
this context, our goal is implement a stationarity test to analyses in
next works. Second, it have been reported that loss of discriminative
power of spectral analysis can occur in some pathological conditions
because rhythms with unstable frequencies might escape outside
the assigned and ﬁxed limits of frequency bands or by the presence
of non linear components that producing harmonics which escaping
the band limits, thus being unaccounted by spectral analysis
(Tobaldini et al., 2009b). Therefore, some authors (Tobaldini et al.,
2009a, 2009b) have shown that symbolic analysis, a non-linear meth-
od of analysis of cardiovascular variability, could be used to solve this
problem, once that it quantiﬁes sympathetic and vagal modulation
without determine limits of the frequency bands. Nevertheless, as
our main objective was to perform an overall investigation of the
cardiovascular variability, including BPV evaluations by spectral anal-
ysis, we believe which the methods of data analysis here used were
also pertinently relevant.
5. Conclusion
In brief, BPV was impaired in hemodynamically stable rats with
chronic MI. Carvedilol treatment partially prevented the BPV de-
crease. Moreover, carvedilol also prevented the well-known cardiac
hypertrophy after infarction. The results of this study provide evi-
dences of the beneﬁt and security of chronic use of carvedilol after MI.
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